Treatment of inflammatory muscle disease in adults

Abstract Inflammatory muscle disease is a term used to designate a heterogeneous group of autoimmune diseases of unknown etiology whose main target is the skeletal muscle. Clinical, histological, and immunopathological criteria are classically used to distinguish polymyositis, dermatomyositis, and i...

Full description

Saved in:
Bibliographic Details
Published in:Joint, bone, spine : revue du rhumatisme bone, spine : revue du rhumatisme, 2010-10, Vol.77 (5), p.390-394
Main Authors: Tournadre, Anne, Dubost, Jean-Jacques, Soubrier, Martin
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal, Murine-Derived - administration & dosage
Autoimmune diseases
azathioprine
Clinical trials
Dermatomyositis
Disease Progression
Glucocorticoids
Glucocorticoids - administration & dosage
Humans
Immunoglobulins
Immunoglobulins, Intravenous
Immunologic Factors - administration & dosage
Immunosuppressive agents
Immunosuppressive Agents - administration & dosage
Inclusion bodies
Inclusion body myositis
Inflammatory diseases
Inflammatory muscle disease
Internal Medicine
Intravenous administration
Joint diseases
Lung Diseases, Interstitial - therapy
Methotrexate
Mycophenolic Acid - administration & dosage
Mycophenolic Acid - analogs & derivatives
Myositis
Myositis - therapy
Polymyositis
Receptors, Interleukin-1 - antagonists & inhibitors
Remission Induction
Rheumatology
Rituximab
Skeletal muscle
Spine
swallowing
Tumor necrosis factor- alpha
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Inflammatory muscle disease is a term used to designate a heterogeneous group of autoimmune diseases of unknown etiology whose main target is the skeletal muscle. Clinical, histological, and immunopathological criteria are classically used to distinguish polymyositis, dermatomyositis, and inclusion body myositis. Major obstacles to controlled therapeutic trials in patients with inflammatory muscle diseases include the heterogeneity of these diseases, their low prevalence, and the absence of validated evaluation criteria. To date, no such trials are available and the treatment is therefore largely empirical. Glucocorticoids are usually given first. Methotrexate is then added in the event of resistance to, or dependency on, glucocorticoid therapy. Methotrexate may be used from the outset in patients with severe disease in an attempt to decrease the glucocorticoid requirements. However, no controlled trials have been conducted to determine whether first-line methotrexate therapy improves outcomes. Intravenous immunoglobulin infusion is a costly treatment option that is reserved for the following situations: refractory dermatomyositis, based on a trial showing superiority over a placebo; myositis with impaired swallowing; and patients with contraindications to immunosuppressants. In patients who fail second-line treatment, which usually consists of methotrexate plus a glucocorticoid, the diagnosis should be carefully reappraised before other treatment options are considered. These options include methotrexate plus azathioprine and recently introduced drugs such as mycophenolate mofetil and rituximab. Caution is in order when considering TNFα antagonist therapy, as cases of paradoxical exacerbation of the muscle involvement have been reported.
ISSN:1297-319X
1778-7254
DOI:10.1016/j.jbspin.2010.04.007